With the breakthrough of science and technology, the once sci-fi idea shone into reality: a few days ago, the world's first "manned flying car" SkyDrive achieved a vertical lift flight at a low altitude of 2 meters, and then, 30 minutes to blast cancer cells, the cost of 100,000 yuan of domestic BNCT anti-cancer boron drug completed the pilot test, from AI to clinical medicine, all fields showed a spurt of development. But among them, the most subversive of human traditional cognition is the technology that inhibits and reverses human aging.
Just past 2021, from Bezos, Buffett and other Forbes 10 richest people to Mayo, Harvard and other top scientific research institutions, have made major breakthroughs around the goal of "longevity and longevity": Mayo's senescent cell scavenger Senolytics, Harvard's NAD+ enhancement technology (its mass production results are the "aging inhibitor molecule" Revital) and GDF11 protein (the "young switch" in human blood), as well as Bezos's heavy warehouse of "cell reprogramming", Google founder Larry Page's elF2B activator... Humanity is ushering in a period of "reverse aging" technology explosion.
Among them, SINCE 2014, NAD+ lifting technology has been confirmed by Massachusetts, Harvard and other laboratory animals to extend life by 0.3-1.3 times, and the motor ability and cognitive function of the elderly group have been significantly reversed, and even the physical strength has increased by 1.6 times. Its practicalization process began with the launch of the first mature product, Reinvigorator, in 2018, from the initial popularity of the rich circle led by Li Ka-shing and Pan Shiyi to the gradual popularization of ordinary high-income people. In a clinical study at the University of Tokyo just last year, the results of significant "reverse growth" of muscles in 65-70-year-olds and the regain of partial hearing loss also reaffirmed the effect of aging intervention.
At the same time, Mayo's first discovery of Senolytics related research has also been published in the "Nature" "Cell" sub-journal - not only to extend the life of mice by 1.3 times, but also to clear the aging cells of the lungs of elderly mice within 4 days by injecting a substance called "α-GalCer", and the effect increased by 100%. Harvard also discovered the GDF11 molecule, which by injection allows old mice to return to youthful levels within 30 days.
The huge breakthrough in cutting-edge technology soon set off a capital carnival of hundreds of billions of aging regulation markets. According to the analysis of the US research institute P&S Intelligence, by 2030, the global market value of industries that inhibit aging and extend life will soar from the current $191.5 billion to $421.4 billion, of which 15 have even achieved IPOs.
This has also attracted a large number of leading business giants such as Google, Amazon, Berkshire and other leading business giants to enter the market, and the relevant technological progress has attracted much attention. Recently, Calico Labs, the founding agency of Google, which has been secretive about the progress of research and development, rarely published a research report: it found a substance ABBV-CLS-7262 that can reverse the aging of the brains of elderly mice within 3 days; on the other hand, the crazy rush for Levito in the wealthy group continued unabated, and Buffett's McLane also joined hands with Reverto R&D company Hobermay at this stage to try to land on the beach.
But what has most recently stirred up the nerves of a group of "life extension maniacs" is the world's richest man, Bezos, who founded Altos with a high profile of $3 billion, and his Nobel Prize technology "cell reprogramming" has successfully returned the cells of a 114-year-old man to the 0-year-old level; in this regard, Musk, who is trying to divide the space dividend with him, choked: "If it doesn't work out, I think he will sue Yama." ”
In this context, the world's top ten pharmaceutical giants have also changed their previous wait-and-see attitude, with Roche, Novartis, AbbVie led by pharmaceutical companies quickly launched a layout, of which AbbVie and Calico launched a cooperation of up to 2.5 billion, Roche, Novartis and Novartis respectively for 4.3 billion and 8.7 billion US dollars respectively to acquire gene therapy companies that are expected to reverse age.
Of course, whether it is for ordinary people or the above-mentioned large pharmaceutical companies with the ultimate goal of monopolizing life extension technology, the most concerned is its practical breakthrough - only when a technology successfully enters people's actual lives can we witness its value. Therefore, the core technologies of Senolytics and Revital, which are located in the first echelon, have become dark horse favorites.
Taking Revital as an example, from 2015 to 2022, Revital has become the first "aging inhibitor" to complete the transformation in Hobermay from a Harvard experimental molecule worth 1.5 million / year, and in the subsequent stage of being introduced to China by JD.com and continued to be sought after by the rich, the global use of NAD+ technology represented by Revital is also expanding.
"I take it in large doses every day because I really see the effect, which encourages me to continue." After Li Ka-shing and Pan Shiyi, Eric Verdin, CEO of the Barck Institute and a professor of medicine at the University of California, said of his "longevity strategy." Not long ago, 84-year-old former Sony president Nobuyuki Izui also revealed in an interview that an important reason for his energy is that he has been taking the substance for a long time, and Izui, who graduated from Waseda University, led Sony to create a revenue of more than 7 trillion yen, and is still active in the commercial front line.
The feedback of capital and markets has further heated up the enthusiasm of researchers around the world. Search for the key technologies of Revital on the authoritative journal library PubMed, and there have been more than 1200 related research papers. Just recently, a team of researchers at Shanghai Jiao Tong University published a study in Cell that the combination of SUPPLEMENTs based on NAD+ boosting in CAR-T immunotherapy increased the 70-day survival rate of tumor mice by nearly 60%.
Just when the VC/PE is still exploring the next wave of "outlets", some rich people in Europe and the United States, led by well-known football players Austin Matz and Madonna Diva superstars, have opened NAD+ injections, although it is difficult to replace the non-invasive oral technology of Revital as the mainstream in the short term, it is also becoming another "delayed choice". Mayo's Senolytics and Harvard GDF11 technologies have also officially entered the first phase of clinical trials, laying the foundation for subsequent practical mass production.
These facts confirm demographer Samuel Preston's view that the biggest driver of life expectancy is the proliferation of technologies in health.